RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid TumorsI won't pretend to know the science as qwerty or scarlett would know. But from a patient's point of view getting 45 weeks of stable disease at this late stage is quite something. And from being in the clinic and going over treatment options with the oncologist, it sounds better than most options at this late stage.